|
|
特异性皮炎发病机制及治疗研究进展
|
Abstract:
近几年随着人们生活压力不断增加，社会环境不断恶化，特应性皮炎(AD)的发病率在逐渐上升，随着病例数目不断增加，对于特应性皮炎的发病机理与治疗手段都有了进一步的认识。通过对特应性皮炎的发病机制与治疗方法进行归纳总结，发现特异性皮炎的发生与多种因素相关，比如患者在日常生活中所面对的心理压力及生存环境、家族遗传情况、免疫力是否低下、皮肤屏障功能异常及感染等因素，目前对于特异性皮炎患者的治疗，我们主要采用加强患者润肤剂的使用意识，必要时采用湿敷、物理手段、外用药物、口服药物及生物抑制剂等治疗方法。
In recent years, with the increasing living pressure and deteriorating social environment, the inci-dence of atopic dermatitis (AD) is increasing gradually. With the increasing number of cases, the pathogenesis and treatment methods of atopic dermatitis have been further understood. By sum-marizing the pathogenesis and treatment methods of atopic dermatitis, it is found that the occur-rence of specific dermatitis is related to a variety of factors, such as psychological pressure and liv-ing environment of patients in daily life, family genetics, low immunity, abnormal skin barrier func-tion, infection and other factors. Currently, for the treatment of patients with specific dermatitis, we mainly strengthen patients’ awareness of the use of emollients, and if necessary, use wet compress, physical means, external drugs, oral drugs and biological inhibitors.
| [1] | Weidinger, S. and Novak, N. (2016) Atopic Dermatitis. The Lancet, 387, 1109-1122.
https://doi.org/10.1016/S0140-6736(15)00149-X |
| [2] | Wollenberg, A., Barbarot, S., Bieber, T., et al. (2018) Con-sensus-Based European Guidelines for Treatment of Atopic Eczema (Atopic Dermatitis) in Adults and Children: Part I. Journal of the European Academy of Dermatology and Venereology, 32, 657-682. https://doi.org/10.1111/jdv.14891 |
| [3] | Drucker, A.M., Wang, A.R., Li, W.Q., et al. (2017) The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. Journal of Investigative Dermatology, 137, 26-30.
https://doi.org/10.1016/j.jid.2016.07.012 |
| [4] | Guo, Y.F., Li, P., Tang, J.P., et al. (2016) Prevalence of Atopic Dermatitis in Chinese Children Aged 1 - 7 Ys. Scientific Reports, 6, Article 29751. |
| [5] | 朱璐, 雷水生, 刘清, 冯雷, 方培炫, 黄美兴. 他克莫司软膏联合耳穴压豆治疗儿童特应性皮炎疗效观察[J]. 亚太传统医药, 2021, 17(8): 108-111. |
| [6] | Nowickad, D. and Grywalska, E. (2018) The Role of Immune Defects and Colonization of Staphylococ-cus aureus in the Pathogenesis of Atopic Dermatitis. Analytical Cellular Pathology, 2018, Article ID: 1956403.
https://doi.org/10.1155/2018/1956403 |
| [7] | 李云卿. 特应性皮炎发病机制与治疗研究进展[J]. 黄河科技学院学报, 2022, 24(2): 51-55.
https://doi.org/10.19576/j.issn.2096-790X.2022.02.010 |
| [8] | Seites, S. and Bieber, T. (2015) Barrier Function and Microbiotic Dysbiosis in Atopic Dermatiyis. Clinical, Cosmetic and Investigational Dermatology, 8, 479-483. https://doi.org/10.2147/CCID.S91521 |
| [9] | Ellinghaus, D., Baurecht, H., Esparza-Gordillo, J., et al. (2013) High-Density Genotyping Study Identifies Four New Susceptibility Loci for Atopic Dermatitis. Nature Genetics, 45, 808-812. https://doi.org/10.1038/ng.2642 |
| [10] | Schaarschmidt, H., Ellinghaus, D., Rodríguez, E., et al. (2015) A Genome-Wide Association Study Reveals 2 New Susceptibility Loci for Atopic Dermatitis. The Journal of Allergy and Clinical Immunology, 136, 802-806.
https://doi.org/10.1016/j.jaci.2015.01.047 |
| [11] | Paternoster, L., Standl, M., Waage, J., et al. (2015) Multi-Ancestry Ge-nome-Wide Association Study of 21,000 Cases and 95,000 Controls Identifies New Risk Loci for Atopic Dermatitis. Nature Genetics, 47, 1449-1456.
https://doi.org/10.1038/ng.3424 |
| [12] | Sonkoly, E., Janson, P., Majuri, M.L., et al. (2010) MiR-155 Is Overex-pressed in Patients with Atopic Dermatitis and Modulates T-Cell Proliferative Responses by Targeting Cytotoxic T Lymphocyte-Associated Antigen 4. The Journal of Allergy and Clinical Immunology, 126, 581-589. https://doi.org/10.1016/j.jaci.2010.05.045 |
| [13] | Rebane, A., Runnel, T., Aab, A., et al. (2014) MicroRNA-146a Al-leviates Chronic Skin Inflammation in Atopic Dermatitis through Suppression of Innate Immune Responses in Keratino-cytes. The Journal of Allergy and Clinical Immunology, 134, 836-847. https://doi.org/10.1016/j.jaci.2014.05.022 |
| [14] | Narla, S. and Silverberg, J.I. (2019) Association between Atopic Dermatitis and Autoimmune Disorders in US Adults and Children: A Cross-Sectional Study. Journal of the American Academy of Dermatology, 80, 382-389.
https://doi.org/10.1016/j.jaad.2018.09.025 |
| [15] | Kazunari, S. and Cezmi, A.A. (2020) Recent Developments and Advances in Atopic Dermatitis and Food Allergy. Allergology International, 69, 204-214. https://doi.org/10.1016/j.alit.2019.08.013 |
| [16] | Sun, D. and Ong, P.Y. (2017) Infectious Complications in Atopic Dermatitis. Immunology and Allergy Clinics of North America, 37, 75-93. https://doi.org/10.1016/j.iac.2016.08.015 |
| [17] | Serrano, L., Patel, K.R. and Silverberg, J.I. (2019) Association be-tween Atopic Dermatitis and Extracutaneous Bacterial and Mycobacterial Infections: A Systematic Review and Me-ta-Analysis. Journal of the American Academy of Dermatology, 80, 904-912. https://doi.org/10.1016/j.jaad.2018.11.028 |
| [18] | 林杨杨, 廉佳, 宫泽琨, 卞亚伟, 刘欣欣, 毕田田, 王莹, 冯小燕, 李钦峰. 克立硼罗软膏治疗儿童轻中度特应性皮炎65例疗效观察[J]. 中国实用儿科杂志, 2021, 36(9): 693-696. https://doi.org/10.19538/j.ek20210906012 |
| [19] | Paller, A.S., Tom, W.L., Lebwohl, M.G., et al. (2016) Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topi-cal Treatment of Atopic Dermatitis (AD) in Children and Adults. Journal of the American Academy of Dermatology, 75, 494-503. https://doi.org/10.1016/j.jaad.2016.05.046 |
| [20] | Schlessinger, J., Shepard, J.S., Gower, R., et al. (2020) Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE1). American Journal of Clinical Dermatology, 21, 275-284. https://doi.org/10.1007/s40257-020-00510-6 |
| [21] | Guttman-Yassky, E., Hanififin, J.M., Boguniewicz, M., et al. (2019) The Role of Phosphodiesterase 4 in the Pathophysiology of Atopic Dermatitis and the Perspective for Its In-hibition. Experimental Dermatology, 28, 3-10.
https://doi.org/10.1111/exd.13808 |
| [22] | Cheape, A.C. and Murrell, D.F. (2017) 2% Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis. Expert Review of Clinical Immunology, 13, 415-423.
https://doi.org/10.1080/1744666X.2017.1304820 |
| [23] | Li, H., Zuo, J. and Tang, W. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology, 9, Article 1048. https://doi.org/10.3389/fphar.2018.01048 |
| [24] | Freund, Y.R., Akama, T., Alley, M.R., et al. (2012) Boron-Based Phosphodiesterase Inhibitors Show Novel Binding of Boron to PDE4 Bimetal Center. FEBS Letters, 586, 3410-3414. https://doi.org/10.1016/j.febslet.2012.07.058 |
| [25] | Zane, L.T., Chanda, S., Jarnagin, K., et al. (2016) Crisaborole and Its Potential Role in Treating Atopic Dermatitis: Overview of Early Clinical Studies. Immunotherapy, 8, 853-866. https://doi.org/10.2217/imt-2016-0023 |
| [26] | 潘延斌, 李建民, 杨猛, 等. MORA生物物理治疗仪联合左西替利嗪治疗慢性荨麻疹的疗效及安全性观察[J]. 解放军预防医学杂志, 2019, 37(6): 136-137. |
| [27] | Deleanu, D. and Nedelea, I. (2019) Biological Therapies for Atopic Dermatitis: An Update. Experimental and Therapeutic Medicine, 17, 1061-1067. https://doi.org/10.3892/etm.2018.6989 |
| [28] | 顾建青, 高翔, 孙劲旅, 等. 度普利尤单抗治疗中重度特应性皮炎初步临床观察[J]. 中华临床免疫和变态反应杂志, 2021, 15(4): 370-375. |
| [29] | Garritsen, F.M. (2018) Use of Oral Immunosuppressive Drug in the Treatment of Dermatisis in the Netherlands. Journal of the European Academy of Dermatology and Venereology, 32, 1336-1342. https://doi.org/10.1111/jdv.14896 |
| [30] | Langans, M., Trvine, A.D. and Weidinger, S. (2020) Atopic Dermatisis. The Lancet, 396, 345-360.
https://doi.org/10.1016/S0140-6736(20)31286-1 |
